This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Looking at the standard of care for Parkinson's Disease patients and the potential of Cerevel Therapeutics orally-administered, selective partial agonist of the dopamine D1 and D5 receptor, Tavapadon

Ticker(s): CERE

Who's the expert?

Institution: Montefiore Medical Center

  • Director, Division of Movement Disorders, who sees 220 patients with Parkinson's Disease yearly
  • Assistant professor, Neurology, Albert Einstein College of Medicine
  • Clinical interest and contributor to journal articles and book chapters on a variety of neurologic topics

Interview Goal
To discuss with a physician the potential of Tavapadon and how it compares to the current standard of care

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.